Valanafusp alfa  (Synonyms: AGT-181; HIRMAb-IDUA)

Valanafusp alfa (AGT-181) is a chimeric monoclonal antibody that fuses human α-L-iduronidase (IDUA) and targets the human insulin receptor (HIR). Valanafusp alfa has brain penetrating properties, making it useful for research on mucopolysaccharidosis type I (MPS I)^[1].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Fusion Protein

Valanafusp alfa (HIRMAb-IDUA) binds to the HIR extracellular domain (ECD) with an EC₅₀ of 0.93±0.07 nM^[2].
Valanafusp alfa (HIRMAb-IDUA) (0.3 μg/mL; 48 h) reduces glycosoaminoglycan accumulation in Hurler fibroblasts by 70% as compared to healthy fibroblasts^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chronic dosing of Valanafusp alfa (AGT-181) (0.2-20 mg/kg; IV) has an excellent safety profile at all doses with no clinical, histologic, or laboratory findings, and no effect on glycemic control in plasma or cerebrospinal fluid^[1].
Valanafusp alfa (AGT-181) (0.2-20 mg/kg; IV) is stable, and shows rapid clearance and the high systemic volume of distribution in Rhesus monkeys^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1815583-32-4

Liquid

Colorless to light yellow

[Valanafusp alfa]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• [1]. Boado RJ, et al. AGT-181: expression in CHO cells and pharmacokinetics, safety, and plasma iduronidase enzyme activity in Rhesus monkeys. J Biotechnol. 2009 Oct 26;144(2):135-41.  [Content Brief]

  [2]. Boado RJ, et al. Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood-brain barrier. Biotechnol Bioeng. 2008 Feb 1;99(2):475-84.  [Content Brief]